KYinno Biotechnology key facts
as of Oct 2026- Developer of oncology drugs intended to accelerate cancer drug discovery and development.
- KYinno Biotechnology is valued at approximately $68.3M as of Oct 2026 (last reported valuation).
- It has raised $59.0M; the latest was Later Stage VC ($34.5M) in Feb 2025.
- Notable investors include Beijing State-owned Capital Operation and Management, Renai Capital, BioTrack Capital, China Everbright, Guochun Li — 9 tracked in total.
- Status: Privately Held (backing).
KYinno Biotechnology's last reported valuation, Oct 2021. Nothing priced has surfaced since.
- ·Watch KYinno Biotechnology: the Monday email on marks, rounds and moves
KYinno Biotechnology funding rounds
No funding rounds for KYinno Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
KYinno Biotechnology valuation
KYinno Biotechnology's last reported valuation was $68.3 million in Oct 2021. No priced round, secondary trade or fund mark has surfaced since.
KYinno Biotechnology investors
9 investors are on record for KYinno Biotechnology, including Beijing State-owned Capital Operation and Management, Renai Capital, BioTrack Capital and China Everbright.
About KYinno Biotechnology
Developer of oncology drugs intended to accelerate cancer drug discovery and development. The company offers immune treatments against cancer, antibody discovery workflows, engineered cellular systems, and next-generation kinase inhibitor design, dedicated to oncology drug discovery and customized product development, enabling these groups to progress their scientific programs effectively.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2017
- Employees
- 130
- Website
- kyinno.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.